App-Quantinova.ai

Impact of prior therapy on efficacy and safety of oral ixazomib-lenalidomide-dexamethasone (IRd) vs placebo-Rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) in TOURMALINE-MM1.

Maria-Victoria Mateos - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Dexamethasone

Carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) and early progression during prior therapy: Secondary analysis from the phase 3 study ASPIRE (NCT01080391).

Heinz Ludwig - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Dexamethasone

Dan T. Vogl - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Dexamethasone

Cyclophosphamide, thalidomide and dexamethasone (CTD) as initial therapy for newly diagnosed multiple myeloma patients.

Jule Franve Vasquez Chavez - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Dexamethasone

Changes in serum alkaline phosphatase levels to predict response to ixazomib-based therapy in patients with newly diagnosed multiple myeloma.

Nidhi Tandon - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Dexamethasone

Cost per median overall month of survival in multiple myeloma patients with 3 lines of therapy or were double refractory.

Eric M. Maiese - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Dexamethasone

Importance of pharmacovigilance in the era of small molecules: Role of pharmacist consultation with ixazomib (IXA) in multiple myeloma (MM).

Heidi Diann Finnes - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Dexamethasone

Placebo-controlled phase III study comparing dexamethasone on day 1 to on day 1-3 with NK1 receptor antagonist and palonosetoron in high emetogenic chemotherapy.

Kunihiro Matsuzaki - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Dexamethasone

Rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with breast cancer.

Lee Steven Schwartzberg - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chemotherapy-induced nausea and vomiting

Dexamethasone

Rolapitant for control of chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic cancer.

Bernardo Leon Rapoport - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chemotherapy-induced nausea and vomiting

Dexamethasone

A randomized, double-blind, placebo-controlled phase II study of prophylactic dexamethasone (dex) therapy for fatigue and malaise due to regorafenib in patient (pts) with metastatic colorectal cancer (mCRC): (KSCC1402/HGCSG1402).

Yuji Miyamoto - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Dexamethasone

A phase I window, dose escalating and safety trial of metformin in combination with induction chemotherapy in relapsed refractory acute lymphoblastic leukemia: Metformin with induction chemotherapy of vincristine, dexamethasone, doxorubicin, and PEG-asparaginase (VPLD).

Julio C. Barredo - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Dexamethasone

Preliminary results of a reduced burden of therapy trial by incorporation of rituximab and intrathecal liposomal cytarabine in children, adolescents and young adults with intermediate (FAB Group B) and high risk (FAB Group C) mature B-cell lymphoma/leukemia.

Stanton Goldman - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

B cell lymphomas

Dexamethasone

Randomized, placebo-controlled, phase III study of aprepitant in preventing chemotherapy-induced nausea and vomiting in children: Analysis by age group.

Hyoung Jin Kang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chemotherapy-induced nausea and vomiting

Dexamethasone

Down-regulation of target gene expression in human white blood cells (hWBCs) by MRX34, a liposomal miR-34 mimic: Next generation sequencing (NGS) results from a first-in-human trial of microRNA cancer therapy.

Kevin Kelnar - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Solid malignancies

Dexamethasone

Effects of MRX34, a liposomal miR-34 mimic, on target gene expression in human white blood cells (hWBCs): qRT-PCR results from a first-in-human trial of microRNA cancer therapy.

Heidi J. Peltier - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Solid malignancies

Dexamethasone

Identifying candidates for prednisone to dexamethasone switch amongst patients with castration-resistant prostate cancer undergoing abiraterone therapy.

Vanessa Sarah Arciero - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Dexamethasone

Minimizing urinary toxicity in daily prostate stereotactic body radiotherapy with urethra dose constraints.

Hyun Kim - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Dexamethasone

Health plan budget impact of introducing elotuzumab in combination with lenalidomide and dexamethasone for relapsed/refractory multiple myeloma in the United States.

Ravi C. Potluri - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Dexamethasone

Efficacy and safety of examethasone, high dose cytarabine, and carboplatin (DHAC) with and without rituximab (R) as a salvage regimen for relapsed/refractory (R/R) lymphoma.

Jeffrey Baron - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lymphomas

Dexamethasone

Filters

4337 Abstracts